By CERBIOS-PHARMA SA
Cerbios-Pharma bringing expanded portfolio to CPHI Frankfurt
Cerbios-Pharma SA, a pharmaceutical company headquartered in Lugano, Switzerland, with more than 40 years of experience in the pharmaceutical industry, will be a prominent presence at November’s rebranded CPHI Frankfurt, presenting its extensive portfolio including generic APIs, SF68® based probiotic strains, and its CDMO services for APIs, HPAPIs, ADCs and Biotechnology.
The Cerbios-Pharma SA stand at Booth 80D50 will be part of the Integrated Pharma Zone at Frankfurt Messe and online.
Cerbios has been a frequent participant at CPhI Worldwide and will once again use this latest iteration to expand its business and client portfolio, present its panel of CDMO services and meet clients and potential customers in-person.
Cerbios goals at CPhI
For 2022, Cerbios will highlight its latest product Recombinant Low Molecular Weight Urokinase (rhLMW Urokinase), along with generic APIs and HPAPI portfolio, and SF68® probiotic based finished products for the treatment of diarrhea and dysbiosis.
Cerbios-Pharma will also present its HPAPI R&D and Commercial capabilities, along with CDMO Antibody-Drug Conjugate (ADC) development and manufacturing services provided through its PROVEO division, offering a fully integrated end-to-end service for ADCs development and manufacturing.
A Cerbios’ team, including key commercial representatives will be present at the physical expo and also accessible online.
Cerbios is a privately held company located in Lugano, Switzerland, specialized in manufacturing Pharma Products and in offering CDMO services.
Cerbios is the ideal CDMO partner from clinical to commercial supply of API, HPAPIs, Payloads, ADCs, Proteins and Antibodies. Services offered include Process & Analytical Development, Scale-up and Clinical Supply, Industrial Validation, Commercial Supply, Full CMC Regulatory Support. Proveo™, a division of Cerbios, was recently created to provide end-to-end development and manufacturing services for ADCs.
Cerbios is also a global leading supplier of a portfolio of Generic APIs primarily used in Oncology and for the treatment of Respiratory and Dermatological disorders. Cerbios has additionally a 40 years’ experience in the probiotics field: the portfolio includes a FDF based on proprietary strain SF68® for treatment of diarrhea and dysbiosis by antibiotics and two new Food Supplements for the management of ACNE & Seborrheic dermatitis and to boost immune response.
Learn more at: https://cerbios.swiss
About CPHI Frankfurt 2022
In its 33rd year, CPhI Worldwide is rebranding as CPHI ‘At the heart of Pharma’, which will continue to be the flagship European annual trade show for pharma ingredients and partner sourcing.
CPHI Frankfurt adopts a hybrid model fusing a large physical expo with an online dimension to make networking and browsing easier and to extend the time frame of the event indefinitely.
For 2022, CPHI Frankfurt is a three-day physical event opening November 1 at the Messe expo center in Frankfurt-am-Main, with the online exhibition opening from September 28.
The previous ‘seven shows in one’ format has been replaced by a larger number of more precisely targeted exhibition zones and online spaces, including Analytical & Lab Zone, APIs, BioProduction, CRO & Clinical Trials, Excipients, Fine Chemicals, Finished Dosage Formulations, ICSE (Outsourcing), InnoPack (Packaging), Integrated Pharma, Natural Extracts, and PMEC (Machinery and Equipment.
CPHI Frankfurt is organised by Informa Markets with further information at: https://www.cphi.com/europe/en/home.html
Click on Cerbios-Pharma at CPHI Frankfurt 2022 for further information.
Click on Cerbios-Pharma SA to see CPHI Frankfurt 2022 exhibitor profile.
Click on Cerbios-Pharma Drug Substances to explore full portfolio.